TY - JOUR T1 - Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinibvs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data JO - Anticancer Research UR - https://doi.org/10.21873/anticanres.16809 PY - 2023/12/30 AU - MOSER SS AU - APTER L AU - SOLOMON J AU - CHODICK G AU - WOLLNER M AU - SIEGELMANN-DANIELI N ED - DO - DOI: 10.21873/anticanres.16809 PB - Anticancer Research USA Inc. VL - 44 IS - 1 SP - 257 EP - 265 Y2 - 2025/08/13 ER -